Climb Bio (CLYM) Long-Term Investments (2021 - 2026)

Climb Bio's Long-Term Investments history runs 5 years deep, the most recent figure standing at $36.7 million for Q1 2026.

• Quarterly Long-Term Investments fell 63.18% year-over-year to $36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.7 million (down 63.18% YoY) and the FY2025 annual result came in at $59.6 million, down 3.31% from the prior year.
• Long-Term Investments was $36.7 million for Q1 2026 at Climb Bio, down from $59.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $102.7 million in Q2 2025 and bottomed at $7.0 million in Q3 2022.
• A 4-year average of $51.8 million and a median of $48.2 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments tumbled 70.53% — and 2025, when it surged 261.86%.
• Climb Bio's Long-Term Investments stood at $7.0 million in 2022, then surged by 785.07% to $61.6 million in 2024, then slipped by 3.31% to $59.6 million in 2025, then slumped by 38.33% to $36.7 million in 2026.
• Business Quant data shows CLYM's Long-Term Investments at $36.7 million in Q1 2026, $59.6 million in Q4 2025, and $88.9 million in Q3 2025.